Zoetis 3Q 2026: Revenue $2.39B, EPS $1.44 — 10-Q Summary
Zoetis reported 3Q 2026 revenue of $2.39B, down 1% YoY, and net income of $1.44B, down 18%. Declines were driven by softer U.S. companion-animal demand, competition, and lower prices, partially offset by livestock growth and favorable exchange rates. Higher restructuring costs also impacted earnings. U.S. companion-animal revenue fell 8%, while U.S. livestock and international revenues rose 5% and 4%, respectively.
How this was made
The 30-second read
Why it matters
The earnings miss highlights soft demand in companion‑animal products, which could affect related suppliers and veterinary services.
Market read
First‑time disclosure of a revenue decline and earnings miss for a large‑cap sector leader, likely influencing animal‑health equities and related supply chains.
What to watch
Restructuring and impairment charges may be one‑time, potentially improving future profitability.
Background
Zoetis is the world’s largest animal health company, listed on NYSE under ZTS.
Ticker impact
Zoetis reported Q3 2026 revenue down 1% YoY and net income down 18%, indicating weaker demand and pricing pressure.
likely pressure as the market prices in the revenue decline and earnings miss.
The 1% revenue drop and 18% net income decline are material for a large‑cap animal health company and were disclosed for the first time.
Market effects
Animal health sector may see broader pressure as demand softness is highlighted.
U.S. companion‑animal market faces pricing headwinds; livestock segment shows modest growth.
Zoetis is a global player; foreign revenue mix slightly offsets U.S. weakness, but overall sentiment remains cautious.
Counterpoint
Livestock growth and foreign‑exchange tailwinds could support earnings if the trend reverses.
Key entities
- CompanyZoetis Inc.
Animal health company reporting Q3 2026 results.
